Mobilization With Movement Versus Joint-Specific Manipulation in De Quervain's Tenosynovitis

April 24, 2025 updated by: Riphah International University

Comparative Study on the Effectiveness of Mobilization With Movement Versus Joint Specific Manipulation on Pain and Function in Patient With Dequervains Tenosynovitis

A comparative study on the effectiveness of mobilization with movement (MWM) versus joint-specific manipulation (JSM) in patients with De Quervain's tenosynovitis typically aims to assess how each technique impacts pain relief and functional improvement. De Quervain's tenosynovitis is an inflammation of the tendons around the thumb and wrist, often causing pain, swelling, and difficulty in performing everyday tasks. The study would likely compare the two interventions by measuring pain levels, range of motion, and overall functional outcomes before and after treatment. MWM involves applying specific, controlled movements while the patient is actively engaging in their joint motion, targeting the tissue's mobility and reducing pain. JSM, on the other hand, focuses on manipulating the joint directly to restore normal function, specifically targeting the wrist and thumb regions affected by the condition.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

A comparative study on the effectiveness of Mobilization with Movement (MWM) versus Joint-Specific Manipulation (JSM) in patients with De Quervain's Tenosynovitis would delve deeper into the physiological mechanisms and clinical outcomes associated with each technique, providing valuable evidence for therapeutic decision-making. De Quervain's Tenosynovitis is a condition characterized by the inflammation of the tendons at the base of the thumb, particularly affecting the abductor pollicis longus and extensor pollicis brevis tendons. This condition is commonly caused by repetitive strain, overuse, or trauma, leading to pain, swelling, and restricted movement, which significantly impacts the patient's daily activities.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
32

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • Pakistan
    • KPK
      • Malakand, KPK, Pakistan, 23060
        • Riphah International University Malakand Campus

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:o Patients clinically diagnosed with De Quervain's tenosynovitis

  • Age between 25-45 years.
  • Positive Finkelstein test.
  • Pain over the first dorsal compartment.
  • Limited wrist and thumb function.
  • Willingness to take part and adhere to the study's guidelines.

Exclusion Criteria:Participants fall in this category would be excluded of the study.

  • Previous surgery of wrist or thumb.
  • Presence of neurological symptoms like numbness, weakeness.
  • Rheumatological conditions like rheumatoid arthritis.
  • Pregnancy.
  • Presence of wrist fracture or osteoporosis.
  • Carpel tunnel syndrome.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Randomized
  • Interventional Model: Single Group Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Joint-specific Manipulation
Group A
Other: Joint Specific Manipulation

Joint Specific Manipulation

  • High-velocity, low-amplitude thrust to the first carpometacarpal joint
  • Radiocarpal wrist mobilization .Grade III-IV applied at end range. 2. Therapeutic excercises:
  • Ball Toss
  • Static web gripping
  • Gentle ROM activities to maintain mobility
  • Isometric exercises in all direction Ergonomics modifications
Placebo Comparator: Mobilization with Movement
Group B
Other: Mobilization with Movement

Mobilization with Movement

  • The proximal row of carpals glides passively radially.
  • Active thumb and wrist movements superimposed on the glide.

Therapeutic excercises:

  • Ball Toss
  • Static web gripping
  • Gentle ROM activities to maintain mobility
  • Isometric exercises in all direction

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Pain Reduction - Measured using the Numeric Pain Rating Scale (NPRS) (0-10 scale).
Time Frame: 6 Months
Pain intensity will be assessed using the Numeric Pain Rating Scale (NPRS), a validated tool where participants rate their pain on a scale from 0 no pain to 10 worst possible pain.
6 Months

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Wrist Function - Assessed with the Patient-Rated Wrist Evaluation (PRWE) (0-100 scale).
Time Frame: 6months
Functional wrist use will be assessed using the Patient-Rated Wrist Evaluation (PRWE), which evaluates pain and disability on a 100-point scale, with higher scores indicating greater impairment. Clinical signs will be assessed using Finkelstein's Test, a standard diagnostic test for De Quervain's tenosynovitis, recorded as positive or negative. Data will be analyzed using pre- and post-intervention comparisons within and between groups to determine the effectiveness of each intervention.
6months

Other Outcome Measures

Other Outcome Measures

For clinical trials, a planned measurement described in the protocol that is used to determine the effect of an intervention/treatment on participants. For observational studies, a measurement or observation that is used to describe patterns of diseases or traits, or associations with exposures, risk factors, or treatment. Types of outcome measures include primary outcome measure and secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Clinical Signs - Evaluated using Finkelstein's Test (Positive/Negative).
Time Frame: 6 months
Clinical Signs will be assessed using Finkelstein's Test, recorded as positive or negative based on the presence of pain during the maneuver.
6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Riphah International University

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Dr.Nadeem Ahmad, MS, Riphah International University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
February 17, 2025

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
February 17, 2025

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
February 17, 2025

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
February 20, 2025

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
April 7, 2025

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
April 9, 2025

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
April 25, 2025

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
April 24, 2025

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
April 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • REC-01001 Khaista Bacha

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings